Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders

Abstract

Continuing low-dose risperidone for up to 3 years appears to be safe and effective in children with disruptive behaviour disorders.

Treating Disruptive Behavior Disorders with Risperidone: A 1-Year, Open-Label Safety Study in Children and Adolescents

“…Weight gain was observed upon risperidone rechallenge in subjects treated previously with placebo, but stabilized over the long term, suggesting that weight gain was an initial effect and generally did not continue with prolonged treatment, nor lead to treatment discontinuation in the vast majority of cases, which is in agreement with previous reports (Turgay et al 2002;Findling et al 2004;Reyes et al 2006b;Reyes et al 2006c). Interestingly, when comparing weight gain patterns in children versus adolescents, the younger cohort experienced transient weight increase while the older cohort had continuous weight reduction over the 1-year period.…”

“…Short-and long-term safety of risperidone as pharmacotherapy for DBDs in children with subaverage intelligence has been demonstrated in over 1,300 children and adolescents in the literature (Turgay et al 2002;Findling et al 2004;Croonenberghs et al 2005;Reyes et al 2006b;Reyes et al 2006c). This open-label extension trial builds on this evidence by examining the safety and tolerability of medication treatment in a normal IQ population.…”

“…Although psychosocial treatments, including family therapy, school intervention, and cognitive-behavioral therapy, are the mainstay of treatment, many subjects experience persistent aggression that interferes with functioning and impairs the ability to participate fully in psychosocial interventions. Pharmacotherapy is recommended for persistent aggression (Kutcher et al 2004), with both short-term, controlled clinical trials (Aman et al 2002;Snyder et al 2002;Reyes et al 2006a) and longer-term open-label trials demonstrating benefit with risperidone treatment in children with DBDs (Turgay et al 2002;Findling et al 2004;Croonenberghs et al 2005;Reyes et al 2006b;Reyes et al 2006c). Risperidone at doses of 0.02-0.06 mg/kg is associated with rapid target symptom improvement (Pandina et al 2006).…”

Survey of Atypical Antipsychotic Prescribing by Canadian Child Psychiatrists and Developmental Pediatricians for Patients Aged under 18 Years

“…[8][9][10][11][12][13][14] As is often the case, controlled trials are rare and are characterized by small sample sizes, diagnostically heterogeneous samples, retrospective designs, short follow-up, and the lack of control groups. [15][16][17][18] Some data support short-term, sustained efficacy in reducing aggression, [19][20][21][22][23][24] tics, 25 and mania. 26,27 Other uses for ATAs, for example, as adjunctive treatment for anxiety and depression, are only supported by data for adults.…”

Atypical and typical antipsychotics in the schools

“…Beyond risperidone there are also a few case reports documenting the usefulness of olanzapine in the management of conduct problems in children with ADHD (Fremaux, Reymann, Chevreuil, & Bentue-Ferrer, 2007). The efficacy of these treatments has been shown in the short term (Jensen et al, 2007) as well as over the long term (Croonenberghs et al, 2005;Reyes, Olah, Csaba, Augustyns, & Eerdekens, 2006;Turgay, Binder, Snyder, & Fisman, 2002). They not only demonstrate efficacy: From an adverse effect standpoint, risperidone and olanzapine have also been found to be generally well tolerated by children prescribed the medication to reduce disruptive behaviors (Jensen et al, 2007).…”